Journal of Virology,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 27, 2025
ABSTRACT
The
imperative
for
developing
robust
tools
to
detect,
analyze,
and
characterize
viruses
has
become
increasingly
evident
as
they
continue
threaten
human
health.
In
this
review,
we
focus
on
recent
advancements
in
studying
with
flow
virometry
(FV),
an
emerging
technique
that
gained
considerable
momentum
over
the
past
5
years.
These
include
application
of
FV
viral
surface
phenotyping,
protein
functionality,
virus
sorting,
vaccine
development,
diagnostics.
With
examples
illustrated
using
primary
data
from
our
studies,
demonstrate
is
a
powerful
yet
underutilized
methodology
that,
when
employed
best
practices
experimental
rigor,
can
be
highly
valuable
individual
virion
heterogeneity,
phenotypes,
virus-antibody
interactions.
also
address
current
challenges
performing
propose
strategies
overcome
these
obstacles,
outline
both
new
experienced
researchers.
Finally,
discuss
promising
future
prospects
within
broader
context
virology
research.
Journal of Extracellular Vesicles,
Год журнала:
2024,
Номер
13(2)
Опубликована: Фев. 1, 2024
Extracellular
vesicles
(EVs),
through
their
complex
cargo,
can
reflect
the
state
of
cell
origin
and
change
functions
phenotypes
other
cells.
These
features
indicate
strong
biomarker
therapeutic
potential
have
generated
broad
interest,
as
evidenced
by
steady
year-on-year
increase
in
numbers
scientific
publications
about
EVs.
Important
advances
been
made
EV
metrology
understanding
applying
biology.
However,
hurdles
remain
to
realising
EVs
domains
ranging
from
basic
biology
clinical
applications
due
challenges
nomenclature,
separation
non-vesicular
extracellular
particles,
characterisation
functional
studies.
To
address
opportunities
this
rapidly
evolving
field,
International
Society
for
Vesicles
(ISEV)
updates
its
'Minimal
Information
Studies
Vesicles',
which
was
first
published
2014
then
2018
MISEV2014
MISEV2018,
respectively.
The
goal
current
document,
MISEV2023,
is
provide
researchers
with
an
updated
snapshot
available
approaches
advantages
limitations
production,
multiple
sources,
including
culture,
body
fluids
solid
tissues.
In
addition
presenting
latest
art
principles
research,
document
also
covers
advanced
techniques
that
are
currently
expanding
boundaries
field.
MISEV2023
includes
new
sections
on
release
uptake
a
brief
discussion
vivo
study
Compiling
feedback
ISEV
expert
task
forces
more
than
1000
researchers,
conveys
research
facilitate
robust
discoveries
move
field
forward
even
rapidly.
Advanced Materials,
Год журнала:
2024,
Номер
36(33)
Опубликована: Июнь 27, 2024
Extracellular
vesicles
(EVs)
are
promising
next-generation
therapeutics
and
drug
delivery
systems
due
to
demonstrated
safety
efficacy
in
preclinical
models
early-stage
clinical
trials.
There
is
an
urgent
need
address
the
immunogenicity
of
EVs
(beyond
apparent
lack
immunotoxicity)
advance
development.
To
date,
few
studies
have
assessed
unintended
immunological
recognition
EVs.
An
in-depth
understanding
EV-induced
clearance
necessary
develop
effective
therapeutic
strategies,
including
approaches
mitigate
when
undesired.
This
article
summarizes
various
factors
involved
potential
strategies
reduce
for
improved
benefit.
Abstract
In
recent
decades,
research
on
Extracellular
Vesicles
(EVs)
has
gained
prominence
in
the
life
sciences
due
to
their
critical
roles
both
health
and
disease
states,
offering
promising
applications
diagnosis,
drug
delivery,
therapy.
However,
inherent
heterogeneity
complex
origins
pose
significant
challenges
preparation,
analysis,
subsequent
clinical
application.
This
review
is
structured
provide
an
overview
of
biogenesis,
composition,
various
sources
EVs,
thereby
laying
groundwork
for
a
detailed
discussion
contemporary
techniques
preparation
analysis.
Particular
focus
given
state‐of‐the‐art
technologies
that
employ
microfluidic
non‐microfluidic
platforms
EV
processing.
Furthermore,
this
discourse
extends
into
innovative
approaches
incorporate
artificial
intelligence
cutting‐edge
electrochemical
sensors,
with
particular
emphasis
single
proposes
current
outlines
prospective
avenues
future
research.
The
objective
motivate
researchers
innovate
expand
methods
analysis
fully
unlocking
biomedical
potential.
Acta Biomaterialia,
Год журнала:
2024,
Номер
180, С. 18 - 45
Опубликована: Апрель 17, 2024
Bacterial
extracellular
vesicles
(BEVs)
are
naturally
occurring
bioactive
membrane-bound
nanoparticles
released
by
both
gram-negative
and
gram-positive
bacterial
species,
exhibiting
a
multifaceted
role
in
mediating
host-microbe
interactions
across
various
physiological
conditions.
Increasing
evidence
supports
BEVs
as
essential
mediators
of
cell-to-cell
communicaiton,
influencing
pathogenicity,
disease
mechanisms,
modulating
the
host
immune
response.
However,
extent
to
which
these
BEV-mediated
actions
can
be
leveraged
predict
onset,
guide
treatment
strategies,
determine
clinical
outcomes
remains
uncertain,
particularly
terms
their
translation
potentials.
This
review
briefly
describes
BEV
biogenesis
internalisation
recipient
cells
summarises
methods
for
isolation
characterization,
understanding
composition
cargo.
Further,
it
discusses
potential
biofluid-associated
biomarkers
diseases,
spanning
cancer
non-cancerous
Following
this,
we
outline
ongoing
human
trials
using
vaccine
development.
In
addition
diagnostics,
this
explores
emerging
research
natural
or
engineered
smart
nanomaterials
applications
anti-cancer
therapy
bone
regeneration.
discussion
extends
key
factors
unlocking
BEVs,
such
standardization
characterisation,
well
other
hurdles
translating
findings
setting.
We
propose
that
addressing
through
collaborative
efforts
well-designed
holds
fully
harnessing
BEVs.
As
field
advances,
suggests
BEV-based
nanomedicine
has
revolutionize
management,
paving
way
innovative
diagnosis,
therapeutics,
personalized
medicine
approaches.
STATEMENT
OF
SIGNIFICANCE:
Extracellular
(EVs)
from
bacteria
serve
multifunctional
biomaterials
fields
biomedicine,
bioengineering,
biomaterials.
majority
current
studies
focus
on
host-derived
EVs,
leaving
gap
comprehensive
bacteria-derived
EVs
(BEVs).
Although
offer
an
attractive
option
drug
delivery
systems,
unique
nanostructure
easy-to-modify
functions
make
them
method
diagnosis
Our
work
among
pioneering
investigating
nanobiomaterials
plays
crucial
development
diseases
therapeutic
interventions.
Advanced Drug Delivery Reviews,
Год журнала:
2024,
Номер
210, С. 115342 - 115342
Опубликована: Май 24, 2024
Chronic
non-healing
wounds
persist
as
a
substantial
burden
for
healthcare
systems,
influenced
by
factors
such
aging,
diabetes,
and
obesity.
In
contrast
to
the
traditionally
pro-regenerative
emphasis
of
therapies,
recognition
immune
system
integral
role
in
wound
healing
has
significantly
grown,
instigating
an
approach
shift
towards
immunological
processes.
Thus,
this
review
explores
process,
highlighting
engagement
system,
delving
into
behaviors
innate
adaptive
cells
chronic
scenarios.
Moreover,
article
investigates
biomaterial-based
strategies
modulation
elucidating
how
adjustment
their
physicochemical
properties
or
synergistic
combination
with
other
agents
drugs,
proteins
mesenchymal
stromal
can
effectively
modulate
different
cells.
Finally
various
based
on
synthetic
biological
nanostructures,
including
extracellular
vesicles,
finely
tune
natural
immunomodulators
therapeutic
nanocarriers
promising
biophysical
properties.
Journal of Extracellular Vesicles,
Год журнала:
2024,
Номер
13(7)
Опубликована: Июль 1, 2024
Abstract
Nowadays,
it
has
become
clear
that
extracellular
vesicles
(EVs)
are
not
a
cellular
waste
disposal
vesicle
but
an
essential
part
of
intercellular
communication
system.
Besides
the
use
EVs
in
biomarker
studies
and
diagnostics,
potential
EV‐therapeutics
been
seen
by
many.
They
provide
unique
properties
for
disease
therapy,
including
strong
immune‐modulatory
actions,
possibility
engineering,
low
immunogenicity,
capability
crossing
biological
barriers.
Proof‐of‐concept
various
pathologies
achieved
preclinical
studies.
However,
clinical
trials
with
have
only
emerging
slowly.
Here,
we
aim
to
comprehensive
overview
current
state‐of‐the‐art
concerning
using
human
therapy.
By
approaching
knowledge
systematic
manner,
were
able
include
21
reports
meta‐analysis
safety
evaluation
efficacy
outcomes.
Overall,
shown
EV‐based
therapy
is
safe
incidence
serious
adverse
events
(SAE;
0.7%
(95%‐CI:
0.1–5.2%),
(AE;
4.4%
0.7–22.2%).
Subgroup
analysis
showed
no
significant
difference
SAE
when
comparing
autologous
versus
allogeneic
administration,
as
well
engineered
non‐engineered
EV
products.
A
significantly
higher
number
AE
was
administration.
relevance
remains
questionable.
Evaluation
outcomes
immunostimulatory,
immunosuppressive
or
regenerative
EV‐therapies
indicated
improvement
majority
treated
patients.
Despite
these
promising
results,
data
need
be
approached
caution
due
high
heterogeneity
manufacturing
methods,
study
design,
reporting
(S)AE.
conclude
presents
opportunity
More
efforts
needed
standardization
harmonization
isolation
characterization
(S)AE
allow
inter‐study
comparison.
